Additional file 2 of Lung immune signatures define two groups of end-stage IPF patients

Additional file 2: Table S1. Immune gene set signatures used in the GSVA pipeline to performed the unbiased clustering. Table S2. Extended gene set signatures with the epithelial and fibrosis associated signatures used in the GSVA to generate the correlation networks. Table S3. Hypergeometric test gene signatures for immune, epithelial and fibrosis related signatures. Table S4. Main clinical characteristics of D#1 y D#2. Table S5. Differences in immune cell signatures across clusters on D#1. Table S6. Differences in clinical characteristics and immune cell signatures across clusters on D#2. Table S7. Differences in clinical characteristics and immune cell signatures across clusters on D#1 filtering by upper lobes. Table S8. Differences in clinical characteristics and immune cell signatures across clusters on D#1 filtering by lower lobes. Table S9. Differences in clinical characteristics and immune cell signatures between upper and lower lobe. Results are expressed as median [95% coefficient interval] or mean (SD) as appropriate. Table S10. Main clinical characteristics of the validation cohort. Table S11. Statistically significant (adjusted p-value < 0.05) genes on the limma test of cluster 2 over cluster 1. Table S12. Gene ontologies enrichment of differentially express genes between the 2 clusters. On the left side the gene ontologies of the cluster 1 are represented (negative values of LgFC Cluster 2/Cluster1), on the right side the gene ontologies of the cluster 2 are represented (positive values of LgFC Cluster 2/Cluster1).